Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News TCT 2023

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

Michael O'Riordan

October 25, 2023

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

News Conference News TCT 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

L.A. McKeown

November 05, 2021

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

News Conference News TCT 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

L.A. McKeown

November 04, 2021

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

News Conference News TCT 2021

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

L.A. McKeown

October 22, 2021

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Todd Neale

October 21, 2020

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Conference News TCT 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Michael O'Riordan

September 29, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

SORT-OUT VI: 3-Year Outcomes Similar With BES, ZES

October 13, 2015

Presentation TCT 2014

State of the (Drug-Eluting) Stent: World-Wide Usage, New Perspectives in Stable CAD, and Remaining Challenges

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi

September 14, 2014

Presentation TCT 2013

Evolution of the AUC Terminology, and Current Recommendations in Stable CAD

Presenter: Manesh Patel

October 28, 2013

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

Advertisement

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

FAVOR III China Adds Strength to Value of QFR-Guided PCI

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

Good Long-term Results With FANTOM BVS, but More Data Needed

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

SORT-OUT VI: 3-Year Outcomes Similar With BES, ZES

State of the (Drug-Eluting) Stent: World-Wide Usage, New Perspectives in Stable CAD, and Remaining Challenges

Evolution of the AUC Terminology, and Current Recommendations in Stable CAD

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content